Stock TARO PHARMACEUTICAL INDUSTRIES LTD.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Taro Pharmaceutical Industries Ltd. Other OTC

Equities

IL0010827181

End-of-day quote Other OTC
Other stock markets
- USD - Intraday chart for Taro Pharmaceutical Industries Ltd.
06-25 Taro Pharmaceutical Industries Ltd.(NYSE:TARO) dropped from S&P Global BMI Index CI
06-24 Sun Pharmaceutical Industries Limited acquired remaining 21.5% stake in Taro Pharmaceutical Industries Ltd. from Krensavage Asset Management, LLC and others for approximately CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Taro Pharmaceutical Industries Ltd.(NYSE:TARO) dropped from S&P Global BMI Index
CI
Taro Pharmaceutical Industries : Sun Pharma Completes Taro Merger Form 6 K
PU
Sun Pharmaceutical Industries Limited acquired remaining 21.5% stake in Taro Pharmaceutical Industries Ltd. from Krensavage Asset Management, LLC and others for approximately
CI
Taro Pharmaceutical's Shareholders Approve Merger With Sun Pharmaceutical
MT
Taro Shareholders Approve Merger with Sun Pharma
PR
Taro Shareholders Approve Merger with Sun Pharma
AQ
Taro Pharmaceutical Industries : Shareholders Approve Merger with Sun Pharma - Form 6-K
PU
Transcript : Taro Pharmaceutical Industries Ltd. - Shareholder/Analyst Call
Transcript : Taro Pharmaceutical Industries Ltd. - Shareholder/Analyst Call
Taro Pharmaceutical Industries : PROVIDES RESULTS FOR YEAR ENDED MARCH 31, 2024 - Form 6-K
PU
Taro Pharmaceutical Industries Fiscal Q4 Earnings, Revenue Rise
MT
Taro: Fiscal Q4 Earnings Snapshot
AQ
Earnings Flash (TARO) TARO PHARMACEUTICAL INDUSTRIES Reports Q4 Revenue $164.9M, vs. Street Est of $156.1M
MT
Taro Provides Results for Year Ended March 31, 2024
BU
Taro Pharmaceutical Industries Ltd. Reports Earnings Results for the Full Year Ended March 31, 2024
CI
Taro Pharmaceutical Industries Ltd. Reports Earnings Results for the Fourth Quarter Ended March 31, 2024
CI
Shareholder Alert: Ademi LLP investigates whether Taro Pharmaceutical Industries Limited has obtained a Fair Price for its Public Shareholders in its transaction with its majority shareholder, Sun Pharmaceutical Industries Limited.
PR
Taro to Release Full Year Results on May 20, 2024
BU
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote 'FOR' Taro Sun Pharma Merger
AQ
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma Merger
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TARO Stock
  4. Stock
  5. News Taro Pharmaceutical Industries Ltd.